Literature DB >> 17079456

Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells.

Eric V Yang1, Anil K Sood, Min Chen, Yang Li, Tim D Eubank, Clay B Marsh, Scott Jewell, Nicholas A Flavahan, Carl Morrison, Peir-En Yeh, Stanley Lemeshow, Ronald Glaser.   

Abstract

Recent studies using ovarian cancer cells have shown that the catecholamine hormones norepinephrine (norepi) and epinephrine (epi) may influence cancer progression by modulating the expression of matrix metalloproteinases (MMP) and vascular endothelial growth factor (VEGF). The purpose of this study is to determine if the stress hormone norepi can influence the expression of MMP-2, MMP-9, and VEGF in nasopharyngeal carcinoma (NPC) tumors by using three NPC tumor cell lines. The NPC cell lines HONE-1, HNE-1, and CNE-1 were treated with norepi. The effects of norepi on MMP-2, MMP-9, and VEGF synthesis were measured by ELISA; functional MMP activity was measured by the invasive potential of the cells using a membrane invasion culture system whereas functional activity of VEGF was analyzed using a human umbilical vein endothelial cell tube formation assay. Norepi treatment increased MMP-2, MMP-9, and VEGF levels in culture supernatants of HONE-1 cells, which could be inhibited by the beta-blocker propranolol. Norepi induced the invasiveness of all NPC cell lines in a dose-dependent manner, which was blocked by CMT-3, an MMP inhibitor, and propranolol. Norepi stimulated the release of functional angiogenic VEGF by HONE-1 cells as well. Finally, HONE-1 cells were shown to express beta-adrenergic receptors as did seven of seven NPC biopsies examined. The data suggest that catecholamine hormones produced by the sympathetic-adrenal medullary axis may affect NPC tumor progression, in part, through modulation of key angiogenic cytokines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079456     DOI: 10.1158/0008-5472.CAN-06-2496

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  146 in total

1.  β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study.

Authors:  Stanley Lemeshow; Henrik Toft Sørensen; Gary Phillips; Eric V Yang; Sussie Antonsen; Anders H Riis; Gregory B Lesinski; Rebecca Jackson; Ronald Glaser
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-20       Impact factor: 4.254

2.  Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.

Authors:  Amal Melhem-Bertrandt; Mariana Chavez-Macgregor; Xiudong Lei; Erika N Brown; Richard T Lee; Funda Meric-Bernstam; Anil K Sood; Suzanne D Conzen; Gabriel N Hortobagyi; Ana-Maria Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

Review 3.  Biobehavioral factors and cancer progression: physiological pathways and mechanisms.

Authors:  Susan K Lutgendorf; Anil K Sood
Journal:  Psychosom Med       Date:  2011-10-21       Impact factor: 4.312

4.  Chronic exposure to stress hormones promotes transformation and tumorigenicity of 3T3 mouse fibroblasts.

Authors:  Melanie S Flint; Andrew Baum; Britteny Episcopo; Kelly Z Knickelbein; Angela J Liegey Dougall; William H Chambers; Frank J Jenkins
Journal:  Stress       Date:  2012-05-16       Impact factor: 3.493

Review 5.  Neuroendocrine influences on cancer progression.

Authors:  Guillermo N Armaiz-Pena; Steve W Cole; Susan K Lutgendorf; Anil K Sood
Journal:  Brain Behav Immun       Date:  2012-06-21       Impact factor: 7.217

Review 6.  Host factors and cancer progression: biobehavioral signaling pathways and interventions.

Authors:  Susan K Lutgendorf; Anil K Sood; Michael H Antoni
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

7.  Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response.

Authors:  S Sud; C O'Callaghan; C Jonker; C Karapetis; T Price; N Tebbutt; J Shapiro; G Van Hazel; N Pavlakis; P Gibbs; M Jeffrey; L Siu; S Gill; R Wong; D Jonker; D Tu; R Goodwin
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

8.  Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors.

Authors:  Shipra Gandhi; Manu Pandey; Nischala Ammannagari; Chong Wang; Mark J Bucsek; Lamya Hamad; Elizabeth Repasky; Marc S Ernstoff
Journal:  Immunotherapy       Date:  2020-02-17       Impact factor: 4.196

9.  Circulating angiogenic biomolecules at rest and in response to upper-limb exercise in individuals with spinal cord injury.

Authors:  Angelo V Vasiliadis; Andreas Zafeiridis; Konstantina Dipla; Nikiforos Galanis; Dimitrios Chatzidimitriou; Antonios Kyparos; Michalis G Nikolaidis; Ioannis S Vrabas
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

10.  VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine.

Authors:  Eric V Yang; Elise L Donovan; Don M Benson; Ronald Glaser
Journal:  Brain Behav Immun       Date:  2007-11-05       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.